<?xml version='1.0' encoding='utf-8'?>
<document id="25156930"><sentence text="The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness."><entity charOffset="47-58" id="DDI-PubMed.25156930.s1.e0" text="hydrocodone" /></sentence><sentence text="The hepatic cytochrome 2D6 (CYP2D6) is a saturable enzyme responsible for metabolism of approximately 25% of known pharmaceuticals" /><sentence text=" CYP interactions can alter the efficacy of prescribed medications" /><sentence text=" Hydrocodone is largely dependent on CYP2D6 metabolism for analgesia, ondansetron is inactivated by CYP2D6, and oxycodone analgesia is largely independent of CYP2D6"><entity charOffset="1-12" id="DDI-PubMed.25156930.s4.e0" text="Hydrocodone" /><entity charOffset="70-81" id="DDI-PubMed.25156930.s4.e1" text="ondansetron" /><entity charOffset="112-121" id="DDI-PubMed.25156930.s4.e2" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.25156930.s4.e0" e2="DDI-PubMed.25156930.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25156930.s4.e0" e2="DDI-PubMed.25156930.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25156930.s4.e0" e2="DDI-PubMed.25156930.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25156930.s4.e1" e2="DDI-PubMed.25156930.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25156930.s4.e1" e2="DDI-PubMed.25156930.s4.e2" /></sentence><sentence text=" The objective was to determine if CYP2D6 medication coingestion decreases the effectiveness of hydrocodone"><entity charOffset="96-107" id="DDI-PubMed.25156930.s5.e0" text="hydrocodone" /></sentence><sentence text="" /><sentence text="This was a prospective observational study conducted in an academic U" /><sentence text="S" /><sentence text=" emergency department (ED)" /><sentence text=" Subjects were included if they had self-reported pain or nausea and were excluded if they were unable to speak English, were less than 18 years of age, had liver or renal failure, or carried diagnoses of chronic pain or cyclic vomiting" /><sentence text=" Detailed drug ingestion histories for the preceding 48 hours prior to the ED visit were obtained" /><sentence text=" The patient's pain and nausea were quantified using a 100-mm visual analog scale (VAS) at baseline prior to drug administration and following doses of hydrocodone, oxycodone, or ondansetron"><entity charOffset="152-163" id="DDI-PubMed.25156930.s12.e0" text="hydrocodone" /><entity charOffset="165-174" id="DDI-PubMed.25156930.s12.e1" text="oxycodone" /><entity charOffset="179-190" id="DDI-PubMed.25156930.s12.e2" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.25156930.s12.e0" e2="DDI-PubMed.25156930.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25156930.s12.e0" e2="DDI-PubMed.25156930.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25156930.s12.e0" e2="DDI-PubMed.25156930.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25156930.s12.e1" e2="DDI-PubMed.25156930.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25156930.s12.e1" e2="DDI-PubMed.25156930.s12.e2" /></sentence><sentence text=" We used a mixed model with random subject effect to determine the interaction between CYP2D6 drug ingestion and study drug effectiveness" /><sentence text=" Odds ratios (ORs) were calculated to compare clinically significant VAS changes between CYP2D6 users and nonusers" /><sentence text="" /><sentence text="A total of 250 (49" /><sentence text="8%) of the 502 subjects enrolled had taken at least one CYP2D6 substrate, inhibitor, or inducing pharmaceutical, supplement, or illicit drug in the 48 hours prior to ED presentation" /><sentence text=" CYP2D6 drug users were one-third as likely to respond to hydrocodone (OR = 0"><entity charOffset="58-69" id="DDI-PubMed.25156930.s18.e0" text="hydrocodone" /><entity charOffset="71-73" id="DDI-PubMed.25156930.s18.e1" text="OR" /><pair ddi="false" e1="DDI-PubMed.25156930.s18.e0" e2="DDI-PubMed.25156930.s18.e0" /><pair ddi="false" e1="DDI-PubMed.25156930.s18.e0" e2="DDI-PubMed.25156930.s18.e1" /></sentence><sentence text="33, 95% confidence interval [CI] = 0" /><sentence text="1 to 0" /><sentence text="8) and more than three times as likely as nonusers to respond to ondansetron (OR = 3"><entity charOffset="65-76" id="DDI-PubMed.25156930.s21.e0" text="ondansetron" /><entity charOffset="78-80" id="DDI-PubMed.25156930.s21.e1" text="OR" /><pair ddi="false" e1="DDI-PubMed.25156930.s21.e0" e2="DDI-PubMed.25156930.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25156930.s21.e0" e2="DDI-PubMed.25156930.s21.e1" /></sentence><sentence text="4, 95% CI = 1" /><sentence text="3 to 9" /><sentence text="1)" /><sentence text=" There was no significant difference in oxycodone effectiveness between CYP2D6 users and nonusers (OR = 0"><entity charOffset="40-49" id="DDI-PubMed.25156930.s25.e0" text="oxycodone" /><entity charOffset="99-107" id="DDI-PubMed.25156930.s25.e1" text="OR" /><pair ddi="false" e1="DDI-PubMed.25156930.s25.e0" e2="DDI-PubMed.25156930.s25.e0" /><pair ddi="false" e1="DDI-PubMed.25156930.s25.e0" e2="DDI-PubMed.25156930.s25.e1" /></sentence><sentence text="53, 95% CI = 0" /><sentence text="3 to 1" /><sentence text="1)" /><sentence text="" /><sentence text="CYP2D6 drug-drug interactions appear to change effectiveness of commonly prescribed drugs in the ED" /><sentence text=" Drug-drug interaction should be considered prior to prescribing CYP2D6 drugs" /><sentence text="" /></document>